Test Catalog

Test Id : INSFT

Order This Test

Insulin, Free and Total, Serum

Download
Overview

Test Catalog

Useful For
Suggests clinical disorders or settings where the test may be helpful

Assessing free (bioactive) insulin concentrations in patients with known or suspected insulin antibodies

Highlights

Patients treated with exogenous insulin preparations might develop autoantibodies against insulin.

 

If significant differences between the total and free insulin concentrations are detected, the presence of insulin antibodies is suspected.

Profile Information
A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test Id Reporting Name Available Separately Always Performed
INSF Insulin, Free, S No Yes
INSTO Insulin, Total, S Yes, (Order as INS) Yes

Method Name
A short description of the method used to perform the test

Electrochemiluminescence Immunoassay (ECLIA)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Insulin, Free and Total, S

Aliases
Lists additional common names for a test, as an aid in searching

Free Insulin, Serum

Specimen Type
Describes the specimen type validated for testing

Serum

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Patient Preparation:

1. Fasting (8 hours)

2. For 12 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Avoid hemolysis

2. Label specimens with corresponding draw times.

3. Serum-gel tubes should be centrifuged within 2 hours of collection.

4. Red-top tubes should be centrifuged and aliquoted within 2 hours of collection.

5. Send specimen refrigerated

Additional Information: If multiple specimens are drawn, send separate order for each specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

0.75 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia OK
Autopsy/postmortem specimen Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
Frozen 180 days
Ambient 24 hours

Useful For
Suggests clinical disorders or settings where the test may be helpful

Assessing free (bioactive) insulin concentrations in patients with known or suspected insulin antibodies

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Insulin is produced by the beta cells of the pancreas. It regulates the uptake and utilization of glucose and is also involved in protein synthesis and triglyceride storage.

 

Circulating insulin antibodies develop after diabetic patients are treated with exogenous insulin preparations. The presence of insulin antibodies has 2 main consequences:

1. Insulin antibodies will directly bind to insulin, making it unavailable for metabolic activity.

2. Insulin antibodies may adversely affect the binding characteristics of insulin in immunoassays, making reliable quantitation difficult.

 

Free (bioactive) insulin could be measured after polyethylene glycol (PEG) precipitation of insulin antibodies and their bound insulin. If insulin antibodies are not present, the free and total insulin should be equivalent. The laboratory will report results of the total insulin (without PEG precipitation) and the free insulin (with PEG precipitation).

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

FREE INSULIN:

2.6-24.9 mcIU/mL

 

TOTAL INSULIN:

2.6-24.9 mcIU/mL

Interpretation
Provides information to assist in interpretation of the test results

If insulin antibodies are not present, the free and total insulin should be equivalent. A significant difference between total and free insulin is suggestive of the presence of insulin antibodies.

 

During prolonged fasting, when the patient's glucose is reduced to less than 40.0 mg/dL, elevated insulin level plus elevated levels of proinsulin and C-peptide suggest insulinoma.

 

In patients with insulin-dependent diabetes mellitus, insulin levels generally decline.

 

In the early stage of noninsulin-dependent diabetes mellitus (NIDDM), insulin levels are either normal or elevated.

 

In the late stage of NIDDM, insulin levels may also decline as levels of proinsulin decrease.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Human antimouse antibodies (HAMA) may interfere with the assay.

 

Hemolysis interferes with this assay, as insulin-degrading peptidases are released from erythrocytes. This assay has 100% cross-reactivity with recombinant human insulin (Novolin R and Novolin N). It does not recognize other commonly used analogues of injectable insulin (ie, insulin lispro, insulin aspart, and insulin glargine).

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P: Autoimmune forms of hypoglycemia. Medicine (Baltimore). 2009 May;88(3):141-153

2. Sapin R, Le Galudec V, Gasser F, Pinget M, Grucker D: Elecsys insulin assay: free insulin determination and the absence of cross-reactivity with insulin lispro. Clin Chem. 2001 Mar;47(3):602-605

3. Sacks DB: Diabetes mellitus. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics 6th ed. Elsevier; 2018:1160-1200

Method Description
Describes how the test is performed and provides a method-specific reference

The Roche Cobas insulin method is a sandwich electrochemiluminescence immunoassay that employs a biotinylated monoclonal insulin-specific antibody and a monoclonal insulin-specific antibody. Insulin in the specimen reacts with both the biotinylated monoclonal insulin-specific antibody (mouse) and the monoclonal insulin-specific antibody (mouse) labeled with a ruthenium complex, forming a sandwich complex. Streptavidin-coated microparticles are added and an interaction occurs between the biotin and streptavidin, binding the complex to the solid phase. The mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell. Application of voltage to the electrode induces the chemiluminescent emission, which is then measured.

 

For free insulin, specimen immunoglobulins are precipitated by adding an equal volume of 25% polyethylene glycol (PEG). The precipitate is removed by centrifugation and the supernatant analyzed using the method described above.(Package insert: Roche Insulin reagent, Roche Diagnostics; 2013)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Thursday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

1 to 4 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

2 weeks

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

83527-Free Insulin

83525-Total Insulin

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
INSFT Insulin, Free and Total, S 48615-9
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
INSTO Insulin, Total, S 20448-7
INSF Insulin, Free, S 6901-3

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports